
Sai Life Sciences (SAILIFE) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Mar 2025Income Metrics
Revenue
5.8B
Gross Profit
4.1B
71.06%
Operating Income
1.2B
20.72%
Net Income
882.7M
15.23%
Balance Sheet Metrics
Total Assets
31.6B
Total Liabilities
10.3B
Shareholders Equity
21.3B
Debt to Equity
0.48
Cash Flow Metrics
Revenue & Profitability Trend
Sai Life Sciences Income Statement From 2022 to 2025
Metric | 2025 | 2024 | 2023 | 2022 |
---|---|---|---|---|
Revenue | 16.9B | 14.7B | 12.0B | 8.7B |
Cost of Goods Sold | 4.7B | 4.5B | 4.6B | 2.9B |
Gross Profit | 12.3B | 10.2B | 7.4B | 5.8B |
Gross Margin % | 72.5% | 69.6% | 61.4% | 66.3% |
Operating Expenses | ||||
Research & Development | - | - | - | - |
Selling, General & Administrative | - | 474.5M | 311.5M | 339.7M |
Other Operating Expenses | 2.7B | 2.4B | 1.3B | 1.1B |
Total Operating Expenses | 2.7B | 2.9B | 1.6B | 1.4B |
Operating Income | 2.7B | 1.7B | 768.3M | 354.7M |
Operating Margin % | 15.8% | 11.3% | 6.4% | 4.1% |
Non-Operating Items | ||||
Interest Income | - | 136.0M | 106.6M | 70.5M |
Interest Expense | 761.6M | 859.1M | 770.6M | 495.7M |
Other Non-Operating Income | - | - | - | - |
Pre-tax Income | 2.3B | 1.1B | 164.1M | 97.0M |
Income Tax | 575.7M | 264.2M | 64.2M | 34.7M |
Effective Tax Rate % | 25.3% | 24.2% | 39.1% | 35.8% |
Net Income | 1.7B | 828.1M | 99.9M | 62.3M |
Net Margin % | 10.0% | 5.7% | 0.8% | 0.7% |
Key Metrics | ||||
EBITDA | 4.4B | 3.1B | 2.0B | 1.4B |
EPS (Basic) | ₹8.83 | ₹3.98 | ₹0.48 | ₹0.30 |
EPS (Diluted) | ₹8.61 | ₹3.98 | ₹0.48 | ₹0.30 |
Basic Shares Outstanding | 192674972 | 207989529 | 207989529 | 207989529 |
Diluted Shares Outstanding | 192674972 | 207989529 | 207989529 | 207989529 |
Income Statement Trend
Sai Life Sciences Balance Sheet From 2022 to 2025
Metric | 2025 | 2024 | 2023 | 2022 |
---|---|---|---|---|
Assets | ||||
Current Assets | ||||
Cash & Equivalents | 911.2M | 236.6M | 699.1M | 1.2B |
Short-term Investments | 4.5B | 1.6B | 1.4B | 1.0B |
Accounts Receivable | 3.5B | 2.6B | 2.8B | 2.4B |
Inventory | 1.2B | 874.4M | 1.4B | 1.3B |
Other Current Assets | 4.9B | - | - | - |
Total Current Assets | 15.0B | 9.5B | 9.6B | 9.5B |
Non-Current Assets | ||||
Property, Plant & Equipment | 14.8B | 0 | 0 | 0 |
Goodwill | 108.6M | 137.7M | 114.3M | 80.5M |
Intangible Assets | - | 137.7M | 114.3M | 80.5M |
Long-term Investments | - | 0 | 2.2M | 0 |
Other Non-Current Assets | 131.1M | - | - | - |
Total Non-Current Assets | 16.6B | 13.3B | 12.2B | 12.2B |
Total Assets | 31.6B | 22.8B | 21.9B | 21.6B |
Liabilities | ||||
Current Liabilities | ||||
Accounts Payable | 3.2B | 2.0B | 2.1B | 2.0B |
Short-term Debt | 1.9B | 4.7B | 4.8B | 4.8B |
Current Portion of Long-term Debt | - | - | - | - |
Other Current Liabilities | 1.3B | - | - | - |
Total Current Liabilities | 7.3B | 7.4B | 7.6B | 7.1B |
Non-Current Liabilities | ||||
Long-term Debt | 1.6B | 4.5B | 4.6B | 4.9B |
Deferred Tax Liabilities | 1.1B | 862.7M | 625.3M | 626.0M |
Other Non-Current Liabilities | - | - | - | - |
Total Non-Current Liabilities | 3.0B | 5.6B | 5.4B | 5.7B |
Total Liabilities | 10.3B | 13.0B | 13.0B | 12.9B |
Equity | ||||
Common Stock | 208.4M | 176.6M | 176.2M | 175.6M |
Retained Earnings | - | 5.5B | 4.7B | 4.6B |
Treasury Stock | - | - | - | - |
Other Equity | - | - | - | - |
Total Shareholders Equity | 21.3B | 9.8B | 8.9B | 8.8B |
Key Metrics | ||||
Total Debt | 3.5B | 9.3B | 9.3B | 9.7B |
Working Capital | 7.7B | 2.1B | 2.1B | 2.3B |
Balance Sheet Composition
Sai Life Sciences Cash Flow Statement From 2022 to 2025
Metric | 2025 | 2024 | 2023 | 2022 |
---|---|---|---|---|
Operating Activities | ||||
Net Income | 2.3B | 1.1B | 164.1M | 97.0M |
Depreciation & Amortization | - | - | - | - |
Stock-Based Compensation | 24.8M | 22.5M | 8.1M | 22.4M |
Working Capital Changes | -2.4B | 318.1M | 225.4M | -888.5M |
Operating Cash Flow | 518.1M | 2.2B | 1.1B | -343.9M |
Investing Activities | ||||
Capital Expenditures | -3.7B | -1.8B | -711.7M | -1.1B |
Acquisitions | -750.0K | 0 | - | - |
Investment Purchases | - | -1.2B | -39.2M | -46.9M |
Investment Sales | - | - | - | - |
Investing Cash Flow | -3.7B | -2.0B | -1.1B | -1.1B |
Financing Activities | ||||
Share Repurchases | - | - | - | - |
Dividends Paid | - | - | - | - |
Debt Issuance | 534.1M | 750.0M | 300.0M | 1.0B |
Debt Repayment | -3.9B | -667.3M | -532.8M | -316.2M |
Financing Cash Flow | 4.4B | 341.3M | -876.2M | 1.5B |
Free Cash Flow | -552.4M | 814.0M | 1.1B | -1.0B |
Net Change in Cash | 1.2B | 451.8M | -915.6M | -13.7M |
Cash Flow Trend
Sai Life Sciences Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
96.16
Forward P/E
53.65
Price to Book
8.10
Price to Sales
9.04
PEG Ratio
0.79
Profitability Ratios
Profit Margin
12.76%
Operating Margin
18.39%
Return on Equity
7.99%
Return on Assets
5.38%
Financial Health
Current Ratio
2.05
Debt to Equity
16.56
Per Share Data
EPS (TTM)
₹8.61
Book Value per Share
₹102.24
Revenue per Share
₹96.04
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
sailife | 172.9B | 96.16 | 8.10 | 7.99% | 12.76% | 16.56 |
Syngene | 270.4B | 52.09 | 5.57 | 10.50% | 13.61% | 12.23 |
Dr. Lal PathLabs | 268.1B | 52.15 | 12.33 | 22.08% | 20.29% | 7.14 |
Vijaya Diagnostic | 108.3B | 71.92 | 13.58 | 17.90% | 21.04% | 39.99 |
Metropolis | 103.3B | 70.83 | 7.76 | 11.96% | 10.89% | 15.30 |
Thyrocare | 70.9B | 67.07 | 12.96 | 16.73% | 14.69% | 4.51 |
Financial data is updated regularly. All figures are in the company's reporting currency.